According to a report published by the American Diabetes Association, 19% to 34% of patients suffering from diabetes are likely to develop diabetic foot ulcers in their lifetime. According to reports, the yearly incidence of foot ulcers ranges from 1.9% to 4.0%, with higher rates (5.0% to 7.5%). The overall numbers have increased from 9.1 million to 26.1 million individuals globally. Therefore, several companies are heavily investing in developing effective solutions for the disease.
The detailed analysis of each phase, molecule type, clinical studies, drug type, route of administration and ongoing product development activities related to diabetic foot ulcers are covered.
Treatment of diabetic foot ulcers must be specialized for everyone based on the severity. For mild ulcers, first, the wound is cleaned to remove the dead tissues and proper dressing is done to keep the area moist. Advanced wound care products and antibiotics may be necessary for moderate ulcers (if an infection is present). Surgical procedures like skin grafts or vascular surgery may be necessary in cases of severe ulcers along with educating patients on foot care and managing blood glucose levels for all phases of the treatment for efficient management of the disease.
This product will be delivered within 3-5 business days.
Report Coverage
The Diabetic Foot Ulcers Drug Pipeline Report by the publisher gives comprehensive insights into diabetic foot ulcer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic foot ulcers. The report includes the analysis of over 50 pipeline drugs and 10+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from diabetic foot ulcer.The detailed analysis of each phase, molecule type, clinical studies, drug type, route of administration and ongoing product development activities related to diabetic foot ulcers are covered.
Diabetic Foot Ulcers Drug Pipeline Outlook
Diabetic foot ulcer is a serious complication that occurs in patients suffering from diabetes as a result of worsening of the condition which includes high blood sugar levels, nerve damage and poor circulation. The chances of developing diabetic foot ulcers drastically increase because individuals with diabetes are more susceptible to infections due to their compromised immune system. High sugar levels in the blood often result in peripheral neuropathy, resulting in loss of sensation in the feet. In this condition, the body’s natural healing process gets hampered along with the loss of sensation in the feet.Treatment of diabetic foot ulcers must be specialized for everyone based on the severity. For mild ulcers, first, the wound is cleaned to remove the dead tissues and proper dressing is done to keep the area moist. Advanced wound care products and antibiotics may be necessary for moderate ulcers (if an infection is present). Surgical procedures like skin grafts or vascular surgery may be necessary in cases of severe ulcers along with educating patients on foot care and managing blood glucose levels for all phases of the treatment for efficient management of the disease.
Diabetic Foot Ulcers - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of diabetic foot ulcer drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Molecule Type
- Monoclonal Antibody
- Peptides
- Small molecule
By Route of Administration
- Oral
- Parenteral
- Others
Diabetic Foot Ulcers - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials for diabetic foot ulcer drugs with 278 pipeline drugs in phase III.Diabetic Foot Ulcers - Pipeline Assessment Segmentation, By Molecule Type
The molecule type categories covered under diabetic foot ulcers include monoclonal antibodies, peptides, and small molecules. Out of all the molecule types, monoclonal antibodies are made to attach to proteins or cells that are affected by an infection or inflammation. The report provides a comparative analysis of the different types of molecules.Diabetic Foot Ulcers Clinical Trials Assessment - Competitive Dynamics
The report for the diabetic foot ulcers drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in diabetic foot ulcers clinical trials:- Cytora Ltd.
- Anterogen Co., Ltd.
- ProgenaCare Global, LLC
- Helse Stavanger HF
- Kerecis Ltd.
- Insel Gruppe AG
- Cynata Therapeutics Limited
- Firstkind Ltd
- Plasmacure BV
Diabetic Foot Ulcers - Pipeline Drugs Profile
Leading drugs in the pipeline are as follows:
Drug: Allogeneic Human Oral Mucosal Stem Cells
The trial studies the efficacy of hOMSCs in patients suffering from chronic diabetic foot ulcers. The trial is sponsored by Cytora Ltd. and is currently under phase I/IIa.Drug: ALLO-ASC-SHEET
The trial studies the efficacy and safety of ALLO-ASC-SHEET in patients suffering from chronic diabetic foot ulcers. The trial is sponsored by Anterogen Co., Ltd. and is currently under phase II.Drug: CYP-006TK
The trial studies the safety, tolerability and efficacy of CYP-006TK in patients suffering from chronic diabetic foot ulcers. The trial is currently under phase I and is sponsored by Cynata Therapeutics.Reasons To Buy This Report
The Diabetic foot ulcers Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic foot ulcers. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within diabetic foot ulcers pipeline insights.Key Questions Answered in the Diabetic Foot Ulcers - Pipeline Assessment Report
- What is the current landscape of diabetic foot ulcer pipeline drugs?
- How many companies are developing diabetic foot ulcers drugs?
- How many phase III and phase IV drugs are currently present in diabetic foot ulcers pipeline drugs?
- Which companies/institutions are leading the diabetic foot ulcers drug development?
- What is the efficacy and safety profile of diabetic foot ulcer pipeline drugs?
- What are the opportunities and challenges present in the diabetic foot ulcers drug pipeline landscape?
- Which company is conducting major trials for diabetic foot ulcers drugs?
- What geographies are covered for diabetic foot ulcer clinical trials?
- What are emerging trends in diabetic foot ulcers clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Diabetic Foot Ulcer
4 Patient Profile: Diabetic Foot Ulcer
5 Diabetic Foot Ulcer: Epidemiology Snapshot
6 Diabetic Foot Ulcer: Market Dynamics
7 Diabetic Foot Ulcer: Key Facts Covered
8 Diabetic Foot Ulcer, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Diabetic Foot Ulcer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Diabetic Foot Ulcer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Diabetic Foot Ulcer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Diabetic Foot Ulcer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Diabetic Foot Ulcer, Key Drug Pipeline Companies
